Douglas Jones
17Patents
4h-index
21Co-inventors
60Inventor score
Filing activity: Feb 24, 1988 → Nov 14, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8618254B2 | Inhibition of AXL signaling in anti-metastatic therapy | Chemistry; Metallurgy | 22 | Active |
| US4920141A | Synergistic biocides of certain nitroimidazoles and aldehydes | Human Necessities | 15 | Expired |
| US9074192B2 | Inhibition of AXL signaling in anti-metastatic therapy | Physics | 6 | Active |
| US11471490B2 | T cells surface-loaded with immunostimulatory fusion molecules and uses thereof | Chemistry; Metallurgy | 6 | Active |
| US9266947B2 | Inhibition of AXL signaling in anti-metastatic therapy | Chemistry; Metallurgy | 3 | Active |
| US9879061B2 | Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis | Physics | 3 | Active |
| US9556248B2 | Hepatocyte growth factor fragments that function as potent met receptor agonists and antagonists | Human Necessities | 2 | Active |
| US8741839B2 | Polypeptides targeting vascular endothelial growth factor receptor-2 and αvβ3 integrin | Human Necessities | 2 | Active |
| US9822347B2 | Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy | Chemistry; Metallurgy | 2 | Active |
| US11498952B2 | Fusion proteins comprising an engineered knottin peptide and uses thereof | Chemistry; Metallurgy | 1 | Active |
| US9234021B2 | Polypeptides targeting vascular endothelial growth factor receptor-2 and alpha V beta 3 integrin | Human Necessities | 1 | Active |
| US10844106B2 | Fusion proteins comprising an engineered knottin peptide and uses thereof | Chemistry; Metallurgy | 1 | Active |
| US12240882B2 | Fusion proteins comprising an engineered knottin peptide and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US11472856B2 | Methods and compositions for promoting immune cell function | Chemistry; Metallurgy | 0 | Active |
| US9441026B2 | Polypeptides targeting vascular endothelial growth factor receptor-2 and alpha V beta 3 integrin | Human Necessities | 0 | Active |
| US11136563B2 | Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy | Chemistry; Metallurgy | 0 | Active |
| US9505822B2 | Polypeptides targeting vascular endothelial growth factor receptor-2 and αvβ3 integrin | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.